Patients & CaregiversHealthcare Professionals - Opens new windowWorldwide - Opens new window
Quick links
HomeAbout MerckProductsNewsroomInvestor RelationsCareersResearchLicensingThe Merck Manuals
Contact Contact Investor Relations
E-mail alerts Sign up for E-mail Alerts
PODCAST Investor Relations Podcast
  RSS RSS

Contact Investor Information

Contact Information for Investors

Institutional Investors and Analysts should contact:
908-423-5881 Monday-Friday 8:30AM - 4:00PM ET


Contact Information for Stockholders

Stockholders should contact:
1-800-522-9114
Monday - Friday, 7 AM - 7 PM CST

Features Available:
1.  Information on shareowner records
2.  Transfer instructions or name changes
3.  Sell shares or to request a certificate
4.  Change of address
5.  To order a dividend reinvestment prospectus
6.  Tax information or duplicate 1099 forms

Company Information:
Stockholder Services Dept., WS3AB-40
Merck & Co., Inc.
One Merck Dr
P O Box 100
Whitehouse Station NJ 08889-0100

Merck News on Call
By calling the toll free number, 1-800-CALL-MRK, (1-800-225-5675),
           you can request - mailed or faxed materials and
           you can hear      - the most recent dividend or earnings information,
                                    - the most recent news releases and
                                    - information about our Annual Meeting

 This number is available 24 hours a day, 7 days a week.

Transfer Agent:
Wells Fargo Shareowner Services

Address for Registered Mail/Federal Express:
161 North Concord Exchange
South St Paul MN 55075

Address for Regular Mail:
P O Box 64856
St Paul MN  55164-0856

Click here to access Wells Fargo Shareowner Services


Printer Friendly Page
 

Stock Quote

Latest prices for Merck stock Stock quote (opens new window)

VIOXX Withdrawal

Information on the voluntary withdrawal of
VIOXX® (rofecoxib)

Important Information

Annual Meeting

Information on the Merck & Co., Inc., Annual Meeting of Stockholders

 
Contact Merck Site Map Privacy Policy Terms of Use Copyright 1995-2008 Merck & Co., Inc.